Objective To observe the clinical effect of tanshinone ⅡA sulfonic acid natrium combined with nicorandil in treating coronary heart disease patients with stable angina pectoris,to investigate the impact on blood lipids and serum homocysteine level.Methods A total of 96 coronary heart disease patients with stable angina pectoris were selected in the Traditional Chinese Medicine Hospital of Urumqi from January 2015 to June 2016,and they were divided into control group and observation group according to random number table,each of 48 cases.Based on conventional treatment,patients of control group received nicorandil,while patients of observation group received tanshinone ⅡA sulfonic acid natrium combined with nicorandil;both groups continuously treated for 4 weeks.Clinical effect,blood lipids index and serum homocysteine level before and after treatment were compared between the two groups,and incidence of adverse reactions were observed during the treatment.Results Clinical effect of observation group was statistically significantly better than that of control group(P<0.05).No statistically significant differences of serum level of TC,TG,LDL-C or HDL-C was found between the two groups before treatment,nor was serum HDL-C level between the two groups after treatment(P>0.05),while serum levels of TC,TG and LDL-C of observation group were statistically significantly lower than those of control group after treatment(P<0.05).No statistically significant differences of serum homocysteine level was found between the two groups before treatment(P>0.05),while serum homocysteine level of observation group was statistically significantly lower than that of control group after treatment(P<0.05).No statistically significant differences of incidence of adverse reactions was found between the two groups during the treatment(P>0.05).Conclusion Tanshinone ⅡA sulfonic acid natrium combined with nicorandil has certain clinical effect in treating coronary heart disease patients with stable angina pectoris,can effectively adjust the blood lipids metabolism and reduce the serum homocysteine level,and is safe.%目的 观察丹参酮ⅡA磺酸钠联合尼可地尔治疗冠心病稳定型心绞痛的临床疗效,探讨其对血脂和血清同型半胱氨酸(Hcy)水平的影响.方法 选取2015年1月-2016年6月乌鲁木齐市中医医院收治的冠心病稳定型心绞痛患者96例,按照随机数字表法分为对照组和观察组,每组48例.在常规治疗基础上,对照组患者给予尼可地尔治疗,观察组患者在对照组基础上联合丹参酮ⅡA磺酸钠注射液治疗;两组患者均连续治疗4周.比较两组患者临床疗效及治疗前后血脂指标、血清Hcy水平,并观察治疗期间不良反应发生情况.结果 观察组患者临床疗效优于对照组(P<0.05).治疗前两组患者血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血清TC、TG、LDL-C水平低于对照组(P<0.05);但治疗后两组患者血清HDL-C水平比较,差异无统计学意义(P>0.05).治疗前两组患者血清Hcy水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血清Hcy水平低于对照组(P<0.05).治疗期间两组患者不良反应发生率比较,差异无统计学意义(P>0.05).结论 丹参酮ⅡA磺酸钠联合尼可地尔治疗冠心病稳定型心绞痛疗效确切,能有效改善患者血脂代谢、降低血清Hcy水平,且安全性较高.
展开▼
